AI Analysis | Feedback

Here are 1-3 brief analogies for Dare Bioscience (DARE):

• A specialized Pfizer focused on women's health.

• A clinical-stage Moderna developing novel women's health products.

• A focused Johnson & Johnson dedicated to innovations in women's reproductive and sexual health.

AI Analysis | Feedback

• Ovaprene: A novel hormone-free, monthly contraceptive intravaginal ring designed to prevent pregnancy.
• DARE-VVA1: A non-hormonal, investigational ovule developed for the treatment of vulvovaginal atrophy (VVA).
• Sildenafil Cream, 3.6% (DARE-GSD): An investigational topical cream designed to treat female sexual arousal disorder (FSAD).
• DARE-BV1: An investigational thermosetting hydrogel being developed for the treatment of bacterial vaginosis.

AI Analysis | Feedback

Dare Bioscience (symbol: DARE) is a clinical-stage biopharmaceutical company focused on women's health. As of its current operational status, the company does not have any products approved for commercialization and therefore does not generate product revenue from sales to other companies or individuals.

Consequently, Dare Bioscience does not currently have any major customers to list, as its revenue is primarily derived from collaboration arrangements and grants rather than from the sale of commercial products.

AI Analysis | Feedback

AI Analysis | Feedback

Sabrina Johnson, President & CEO, Principal Financial Officer

Sabrina Johnson is the founder and CEO of Daré Bioscience, which she established in 2015. She has a robust background spanning over 25 years in life sciences, including finance, global marketing, product development, and bench research. Prior to founding Daré, she served as President of WomanCare Global Trading, a global provider of women's health products. She also held CFO/CAO positions at the California Institute for Biomedical Research and CFO/COO roles at Cypress Bioscience, Inc. At Cypress Bioscience, she was instrumental in executing mergers, acquisitions, and divestitures, including a transaction that resulted in a 160% premium for shareholders with a deal valued over $250 million when the company was sold. She has also held marketing and sales positions at Advanced Tissue Sciences and began her biotechnology career as a research scientist at Baxter Healthcare.

MarDee Haring-Layton, Chief Accounting Officer

MarDee Haring-Layton joined Daré Bioscience in January 2018 and has been the Chief Accounting Officer since January 2024, also serving as the principal accounting officer. She previously held the role of Vice President, Accounting & Finance since October 2018. Ms. Haring-Layton is an experienced finance and accounting executive with over 20 years of experience in financial reporting and accounting operations across both public and private companies, including a background in Big 4 public accounting. Before joining Daré, she served as Chief Financial Officer of e.Digital Corporation, a publicly traded IP licensing and development company, from 2010 to 2017.

David Friend, Ph.D., Chief Scientific Officer

David Friend, Ph.D., was appointed Chief Scientific Officer of Daré Bioscience in June 2018. He brings extensive expertise in product development, covering stages from pre-IND through Phase III and NDA submissions to the FDA. His background includes a deep understanding of CMC, intellectual property, and product formulation science, particularly in vaginal drug delivery systems such as gels, creams, tablets, intravaginal rings, and controlled release polymers. Prior to Daré, Dr. Friend served as Chief Scientific Officer at Evofem Biosciences and as Director of Product Development at CONRAD, an organization focused on contraceptive research. He also held the position of Vice President of Research at Vyteris, a company developing transdermal delivery systems, and has experience at other pharmaceutical companies including Delsys Pharmaceutical, Vascular Therapeutics, CIBUS Pharmaceuticals, and SRI International.

Mark Walters, Vice President - Operations

Mark Walters has served as the Vice President - Operations for Daré Bioscience since 2015. His role involves overseeing the company's operational activities.

Elizabeth Proos, Vice President, Product Development

Elizabeth Proos joined Daré Bioscience in November 2019 following the acquisition of DARE MB Inc. and currently serves as the Vice President of Product Development. In this role, she is responsible for technical and strategic product development, implementing best practices in product development and program management. Ms. Proos also leads the strategy and product development for DARE-LARC1, a user-controlled, long-acting, reversible contraceptive, and manages a cross-functional R&D and product development team along with key external partners. Her career spans over 23 years in drug delivery science and the development of combination products and medical devices, where she has advanced novel products through clinical development across various therapeutic areas. Prior to Daré Bioscience, she held leadership and technical positions at BD, Lantheus Medical Imaging, Epic Therapeutics (a subsidiary of Baxter Healthcare), and Etex Corporation.

AI Analysis | Feedback

The key risks to Dare Bioscience (DARE) are primarily centered around its financial viability, regulatory hurdles for its product pipeline, and its listing status on Nasdaq.

1. Financial Health and Going Concern: Dare Bioscience faces substantial doubt about its ability to continue as a going concern within the next 12 months. This is due to ongoing losses, negative operating cash flow, and uncertainty regarding the timing and magnitude of future revenue. The company has a reported working capital deficit of approximately $12.6 million as of June 30, 2025, and is characterized by a rapid cash burn. Its Altman Z-Score of -9.68 indicates a high risk of bankruptcy within two years. The company's minimal revenue, such as $2,262 in Q3 2025, further underscores its financial challenges and reliance on grant funding and partnerships to advance its pipeline.
2. Regulatory and Commercialization Challenges for Products: A significant risk stems from the regulatory pathway and commercialization of its product candidates. For instance, DARE to PLAY Sildenafil cream, a potential "near-term revenue driver," is currently available as a Section 503B compounded product, meaning it is not FDA approved. This status can raise concerns among consumers and healthcare providers regarding its safety and effectiveness. There is also a risk that the FDA could change the conditions under which 503B-registered outsourcing facilities can compound such drug substances or distribute compounded products. Furthermore, Dare Bioscience has limited experience and infrastructure for commercializing products, which could impede the successful launch and market acceptance of its offerings, even if approved.
3. Nasdaq Delisting Risk: Dare Bioscience is facing potential delisting from the Nasdaq Capital Market. The company received a notification from Nasdaq for non-compliance with the exchange's minimum market value requirement of $35 million. While Dare Bioscience plans to request a hearing to prevent delisting, there is no guarantee that the Nasdaq Hearing Panel will grant additional time or that the company will be able to meet the compliance requirement within any extension period.

AI Analysis | Feedback

AI Analysis | Feedback

Dare Bioscience (symbol: DARE) focuses on women's reproductive health, with several products in its pipeline targeting significant addressable markets.

Main Products and Addressable Markets:

• XACIATO (clindamycin phosphate vaginal gel) for Bacterial Vaginosis (BV):

  The global bacterial vaginosis treatment market was valued at approximately USD 1.23 billion in 2024 and is projected to reach USD 2.37 billion by 2032. Other estimates for the global market include USD 3.79 billion in 2025, reaching USD 6.88 billion by 2032. The bacterial vaginosis market across the top 7 markets (US, EU4, UK, and Japan) was valued at USD 806.4 million in 2024 and is projected to reach USD 1,450.4 million by 2035. North America dominates the bacterial vaginosis Rx drug market, holding a substantial 40.5% market share in 2023.

• Ovaprene (hormone-free monthly intravaginal contraceptive):

  This product addresses the non-hormonal contraceptives market. The global non-hormonal contraceptives market size was valued at USD 19.9 billion in 2024 and is expected to reach USD 39.1 billion by 2034. Another report estimates the global non-hormonal contraception market at USD 30.67 billion in 2023, poised to grow to USD 54.06 billion by 2032. The U.S. non-hormonal contraceptives market accounted for USD 5.8 billion in 2024.

• Sildenafil Cream, 3.6% (for Female Sexual Arousal Disorder - FSAD):

  This product targets the female sexual dysfunction treatment market. The global female sexual dysfunction treatment market size was valued at USD 489.6 million in 2024 and is projected to grow to USD 1,329.5 million by 2032. Other estimates for the global market include USD 542.97 million in 2024, growing to USD 1,443.44 million by 2032. The North American market for female sexual dysfunction treatment was valued at USD 435.9 million in 2024 and is anticipated to continue to dominate. The U.S. female sexual dysfunction treatment market size is projected to grow significantly, reaching an estimated value of USD 782.3 million by 2032.

• DARE-HRT1 (combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy, including vulvar and vaginal atrophy):

  The global vulvar and vaginal atrophy therapy market is projected to reach US$3.8 billion in 2025 and is expected to reach US$5.4 billion by 2032. The atrophic vaginitis treatment industry is valued at USD 3.21 billion in 2025 and is projected to reach USD 6.93 billion by 2035 (global). The U.S. vaginal atrophy treatment market size was valued at USD 1.19 billion in 2024 and is projected to grow to USD 1.63 billion by 2032. Dare Bioscience also anticipates that its proprietary monthly hormone therapy via the 503B compounding pathway creates entry into the estimated USD 4.5 billion compounded hormone therapy market, likely referring to the U.S. market.

• Programs for Preterm Birth (e.g., DARE-FRT1/PTB1):

  The global preterm labor treatment market size was valued at USD 1.20 billion in 2024 and is expected to grow to USD 2.63 billion by 2033. Another estimate for the global premature labor treatment market size is USD 1,603.4 million in 2025, reaching USD 3,352.96 million by 2033. The preterm births and PROM testing market is projected to grow from USD 2.0 billion in 2025 to USD 2.7 billion by 2035 (global). North America holds 33.05% of the global premature labor treatment market in 2025.

• Fertility Products (general, including IVF):

  The global fertility services market was estimated at USD 42.23 billion in 2023 and is projected to reach USD 70.27 billion by 2030. The global in vitro fertilization (IVF) market size was estimated at USD 25.3 billion in 2023 and is projected to reach USD 37.4 billion by 2030. The U.S. in-vitro fertilization services market was valued at USD 5,910.98 million in 2024 and is projected to reach USD 13,944.38 million by 2032.

AI Analysis | Feedback

Dare Bioscience (DARE) anticipates several key drivers for future revenue growth over the next two to three years, primarily stemming from the commercialization of its pipeline products in women's health:

1. Launch of DARE to PLAY™ Sildenafil Cream: The company expects its first revenue-generating product, DARE to PLAY™ Sildenafil Cream, to launch in the fourth quarter of 2025 through a 503B compounding pathway. This product is designed for topical, on-demand use in women with female sexual arousal disorder.
2. Commercialization of DARE-HRT1: Daré Bioscience plans to introduce DARE-HRT1, a proprietary monthly hormone therapy delivered via a vaginal ring, by late 2026. This product aims to enter the estimated $4.5 billion compounded hormone therapy market, expanding the company's addressable market to include menopause symptom relief.
3. Commercialization of Vaginal Probiotics: Following the availability of DARE to PLAY Sildenafil Cream, Daré Bioscience intends to commercialize vaginal probiotics in the consumer health market.
4. Advancement of Ovaprene®: While still in clinical development, the investigational hormone-free intravaginal contraceptive, Ovaprene®, has shown positive interim results in its Phase 3 study and is a significant asset that could drive future revenue upon successful completion of trials and market entry. This product represents a first-in-category, hormone-free solution.
5. Progress in Grant-Funded Programs: Continued progress in grant-funded pipeline programs, such as DARE-HPV for human papillomavirus infection and DARE-LARC1 for long-acting contraception, could lead to future product commercialization and revenue streams beyond the initial launches.

AI Analysis | Feedback

Share Issuance

• Dare Bioscience entered into a common stock purchase agreement with Lincoln Park Capital Fund, LLC in October 2024, authorizing the sale of up to $15 million in common stock over a 24-month period.
• In August/September 2023, the company completed a registered direct offering of common stock and warrants, resulting in $7.0 million in aggregate gross proceeds.
• Post Q2 2025 (July 2025), Dare Bioscience raised $17.6 million in net proceeds through common stock sales, primarily from At-The-Market (ATM) offerings.
• A 1-for-12 reverse stock split was implemented in July 2024 to address Nasdaq's minimum bid price requirement.

Inbound Investments

• As of October 2025, Dare Bioscience received a $4.0 million non-dilutive grant installment, bringing the total received to approximately $41.8 million out of a potential $49 million commitment to support the DARE-LARC1 contraceptive program.
• In December 2023, the company secured a royalty-backed financing agreement providing $5 million at closing and the option for an additional $7 million in tranches against future XACIATO royalties and milestones.
• In 2024, the company received $3.5 million in grant funding as part of the multi-year grant agreement for DARE-LARC1.

Capital Expenditures

• Over the last 12 months (as of October 2025), Dare Bioscience's capital expenditures were approximately -$284,459.
• The company's primary capital usage focuses on staff-related expenses, clinical trials, regulatory activities, contract manufacturing services, and third-party research and development, rather than significant investments in physical assets.